These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 33729874)

  • 1. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
    Hache G; Rolain JM; Gautret P; Deharo JC; Brouqui P; Raoult D; Honoré S
    Microb Drug Resist; 2021 Mar; 27(3):281-290. PubMed ID: 33729874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    Juurlink DN
    CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
    [No Abstract]   [Full Text] [Related]  

  • 3. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
    Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
    Pani A; Lauriola M; Romandini A; Scaglione F
    Int J Antimicrob Agents; 2020 Aug; 56(2):106053. PubMed ID: 32534189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
    Mégarbane B; Scherrmann JM
    J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
    [No Abstract]   [Full Text] [Related]  

  • 7. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
    Li C; Cheng G
    Front Immunol; 2020; 11():1969. PubMed ID: 32849658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
    Cavalcanti AB; Zampieri FG; Rosa RG; Azevedo LCP; Veiga VC; Avezum A; Damiani LP; Marcadenti A; Kawano-Dourado L; Lisboa T; Junqueira DLM; de Barros E Silva PGM; Tramujas L; Abreu-Silva EO; Laranjeira LN; Soares AT; Echenique LS; Pereira AJ; Freitas FGR; Gebara OCE; Dantas VCS; Furtado RHM; Milan EP; Golin NA; Cardoso FF; Maia IS; Hoffmann Filho CR; Kormann APM; Amazonas RB; Bocchi de Oliveira MF; Serpa-Neto A; Falavigna M; Lopes RD; Machado FR; Berwanger O;
    N Engl J Med; 2020 Nov; 383(21):2041-2052. PubMed ID: 32706953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
    Gautret P; Honoré S; Lagier JC; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106236. PubMed ID: 33408025
    [No Abstract]   [Full Text] [Related]  

  • 10. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.
    García-Fernández A; Ramos-Ruiz P; Ibáñez-Criado A; Moreno-Pérez Ó; Cambra-Poveda C; Martínez-Martínez JG;
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):108-111. PubMed ID: 33077410
    [No Abstract]   [Full Text] [Related]  

  • 11. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
    Furtado RHM; Berwanger O; Fonseca HA; Corrêa TD; Ferraz LR; Lapa MG; Zampieri FG; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Avezum A; Manoel ALO; Piza FMT; Martins PA; Lisboa TC; Pereira AJ; Olivato GB; Dantas VCS; Milan EP; Gebara OCE; Amazonas RB; Oliveira MB; Soares RVP; Moia DDF; Piano LPA; Castilho K; Momesso RGRAP; Schettino GPP; Rizzo LV; Neto AS; Machado FR; Cavalcanti AB;
    Lancet; 2020 Oct; 396(10256):959-967. PubMed ID: 32896292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
    Machiels JD; Bleeker-Rovers CP; Ter Heine R; Rahamat-Langendoen J; de Mast Q; Ten Oever J; Bousema T; van Crevel R; Wertheim HF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106056. PubMed ID: 32674929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
    Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
    Cochin M; Touret F; Driouich JS; Moureau G; Petit PR; Laprie C; Solas C; de Lamballerie X; Nougairède A
    Antiviral Res; 2022 Jan; 197():105212. PubMed ID: 34838583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
    Jordaan P; Dumotier B; Traebert M; Miller PE; Ghetti A; Urban L; Abi-Gerges N
    Toxicol Sci; 2021 Apr; 180(2):356-368. PubMed ID: 33483756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
    Szendrey M; Guo J; Li W; Yang T; Zhang S
    J Pharmacol Exp Ther; 2021 May; 377(2):265-272. PubMed ID: 33674391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
    Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
    Nicol MR; Joshi A; Rizk ML; Sabato PE; Savic RM; Wesche D; Zheng JH; Cook J
    Clin Pharmacol Ther; 2020 Dec; 108(6):1135-1149. PubMed ID: 32687630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
    Damle B; Vourvahis M; Wang E; Leaney J; Corrigan B
    Clin Pharmacol Ther; 2020 Aug; 108(2):201-211. PubMed ID: 32302411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.